Cytokinetics(US:CYTK) Globenewswire·2025-10-10 17:29Core Viewpoint - Rosen Law Firm is reminding investors who purchased Cytokinetics, Inc. common stock between December 27, 2023, and May 6, 2025, of the upcoming lead plaintiff deadline on November 17, 2025, for a class action lawsuit related to misleading statements about the company's drug approval process [1][5]. Group 1: Class Action Details - Investors who bought Cytokinetics common stock during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm or through their website [3][6]. - The lawsuit alleges that Cytokinetics made false statements regarding the timeline for the New Drug Application (NDA) submission and approval for aficamten, which misled investors about the regulatory process [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in recovering hundreds of millions of dollars for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and securing over $438 million for investors in 2019 [4].